## **Prescribing Guidance for Moderately to Severely Frail Patients**

**NHS** Bath and North East Somerset,

Swindon and Wiltshire

Severe frailty (Rockwood score 7-9): dependent for personal care. Moderate frailty (Rockwood score 5-6): need help with personal care. If only mild frailty (Rockwood score 3-4) continue usual prescribing. Rockwood calculator: https://bit.ly/3LW27BJ

## Deprescribing algorithms for specific drugs and further information in PrescQIPP IMPACT tool, available here: bit.ly/3LN1VFc

DIABETE	S Code as	moderate or severe frailty for QOF	
Moderate	Aims	Control symptoms and avoid metabolic complications.	
Frailty	Ains	QOF HbA1c target: <75 mmol/mol. Generally avoid HbA1c <60.	
Traity	Actions	If adjusting gliclazide/sulphonylurea or insulin dose, ensure BGLs are	
	Actions	checked to avoid significant or symptomatic hyperglycaemia.	
		Review Rx with renal function (e.g. avoid metformin if eGFR <30ml/min)	
		& after change in care setting owing to changes in adherence & diet.	
		Dietary restriction not appropriate if low BMI or losing weight.	
Severe	Aims	Control symptoms and avoid metabolic complications. No "target"	
Frailty	AIIIIS	HbA1c. Stop routine monitoring unless clinical concern.	
Francy	Actions	De-escalate treatment where possible. Do not stop insulin in T1DM.	
	ACIONS	Continue to monitor BGLs if on sulphonylurea or insulin.	
		ways measure lying and standing in >75yrs. Review after a fall.	
Moderate	Aims	BP <160/100 & no postural drop. <u>Optimal BP for 75yrs+ may be 165/85</u> .	
Frailty	Actions	Avoid alpha blockers and thiazides	
Severe	Aims	No BP target	
Frailty	Actions	Stop anti-hypertensives	
	FEROL RE	DUCTION	
Moderate	Aims	Primary prevention reduces CV risk if <75 yrs & no risk factors, or if <85	
Frailty		yrs with risk factors (particularly diabetes).	
	Actions	If for primary prevention and not diabetic then stop Rx.	
		If for secondary prevention (CV/stroke/PVD) or diabetic - continue.	
Severe	Aims	No added value in the severely frail.	
Frailty	Actions	Stop cholesterol drugs regardless of indication.	
HEART FAILURE with reduced ejection fraction If normal NTpro-BNP consider other diagnosis			
Moderate	Aims	Symptom control & avoidance of hospital admission.	
Frailty		Optimise Rx with loop diuretic (bumetanide has lowest ACB score) +	
		ACEi/ARB + $\beta$ blocker. NNT 15 to prevent one death/year.	
	Actions	In confirmed HF, continue treatment as advised by specialist. Involve	
		Community HF service. If not confirmed HF, consider titrating down	
		diuretics & alternative causes of oedema eg dependency, amlodipine.	
Severe	Aims	Continue Rx to reduce risk of terminal CCF.	
Frailty	Actions	Manage symptoms, less concern regarding renal function. Continue	
		ACE & diuretic even where BP is low, as long as not dizzy or syncope.	
		Furosemide in syringe driver is an option at end of life.	
<b>ANGINA</b>	Refer/discu	uss if uncontrolled on 2 agents or first line treatments not tolerated	
Moderate	Aims	Usually fewer symptoms as mobility decreases.	
Frailty	Actions	If asymptomatic or falling/hypotensive stop one drug at a time.	
		Stop ISMN or Ca channel blocker first. Continue aspirin & statin.	
Severe	Aims	Reduce & stop angina drugs; symptoms less likely if inactive/immobile.	
Frailty	Actions	Stop aspirin and statin: NNT to prevent ischaemic event 250/year, and	
		no significant reduction in mortality.	

OSTEOPOROSIS				
Moderate	Aims	Prevent fractures. Calculate FRAX score for all.		
Frailty	Actions	Prescribe oral bisphosphonates, or iv zoledronic acid, if age ≥70 and/or		
-		previous hip or vertebral #. Consider stopping after 5 years.		
		Check tolerance at 12-16 weeks, and adherence yearly.		
Severe	Aims	Immobility increases fracture risk, but no benefit in initiating anti-		
Frailty		resorptive drugs in last year of life.		
-	Actions	Stop bisphosphonates if prognosis <1 year or if bed-bound.		
		Do not stop or delay denosumab without a plan from specialist team.		
OVER ACTIVE BLADDER See local guidelines: https://bit.ly/3yawG0M				
Moderate	Aims	Avoid anticholinergic OAB drugs, all have ACB score = 3.		
Frailty		2 year mortality: 20% with total ACB score ≥4 vs 7% with ACB score 0.		
-	Actions	Stop anticholinergics. If drug treatment needed use mirabegron.		
		Refer for continence support.		
Severe	Aims	Review need for any OAB drug.		
Frailty	Actions	Avoid/stop drug treatment if significant functional or cognitive		
		impairment; incontinent; catheterised; immobile.		
DEMENTIA Consider referral to RICE/Old age psychiatry				
Moderate	Aims	Relieve symptoms, slow progression. Agree & document advanced		
Frailty		care plans.		
	Actions	Continue dementia drugs unless side effects > perceived benefits.		
		Minimise anticholinergic burden (ACB) e.g. antimuscarinics,		
		antihistamine, tricyclics.		
		Taper & stop antipsychotics after 12 weeks if only for dementia. If		
		physical aggression resumes, repeat weaning attempts at least yearly.		
Severe	Aims	Minimise medication burden		
Frailty	Actions	Continue dementia drugs if benefit to behavioural symptoms.		
		Stop if side effects or unable to take e.g. unreliable swallow.		
		Minimise other drugs to reduce risk of delirium.		
		y not to exceed: Morphine 60mg bd; Fentanyl 25 mcg patch		
Moderate	Aims	Use lowest effective dose of analgesia - significant risk of side effects		
Frailty		e.g. gabapentinoids & falls.		
		Stop if cause of pain resolved e.g. post joint replacement in OA.		
	Actions	Regular paracetamol first-line, continue if other analgesics added.		
		Avoid amitriptyline as highly anticholinergic.		
		Co-prescribe laxatives with opiates: stimulant + softener.		
		Taper opioids when stopping e.g. 10% every 1-2 weeks.		
		Avoid NSAID if possible, if no other option & eGFR >30: 2 weeks max,		
-	A :	plus gastroprotection.		
Severe	Aims	Titrate down analgesia to lowest effective dose and stop if able.		
Frailty	Actions	Titrate down doses with weight loss. Titrate all drugs down if delirium.		
		Consider pain or constipation as a cause of delirium.		

NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board. Based on author consensus following literature review and agreed by CoE teams across BSW. Date: September 2022 Review date: September 2023